Adolescent- and adult-onset neuroblastic tumor: A retrospective multicenter observational study of patients diagnosed in France between 2000 and 2020.
adolescent and young adult cancer
adult‐onset pediatric cancer
ganglioneuroblastoma
neuroblastoma
peripheral neuroblastic tumor
pheochromocytoma
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
22 May 2024
22 May 2024
Historique:
revised:
27
04
2024
received:
07
01
2024
accepted:
30
04
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
Adult- and adolescent-onset neuroblastomas are rare, with no established therapy. In addition, rare pheochromocytomas may harbor neuroblastic components. This study was designed to collect epidemiological, diagnostic and therapeutic data in order to better define the characteristics of malignant peripheral neuroblastic tumors (MPNT) and composite pheochromocytomas (CP) with MPNT. Fifty-nine adults and adolescents (aged over 15 years) diagnosed with a peripheral or composite neuroblastic tumor, who were treated in one of 17 institutions between 2000 and 2020, were retrospectively studied. Eighteen patients with neuroblastoma (NB) or ganglioneuroblastoma (GNB) had locoregional disease, and 28 patients had metastatic stage 4 NB. Among the 13 patients with CP, 12 had locoregional disease. Fifty-eight percent of the population were adolescents and young adults under 24 years of age. The probability of 5-year event-free survival (EFS) was 40% (confidence interval: 27%-53%). Outcomes were better for patients with localized tumor than for patients with metastases. For patients with localized tumor, in terms of survival, surgical treatment was the best therapeutic option. Multimodal treatment with chemotherapy, surgery, radiotherapy, and immunotherapy-based maintenance allowed long-term survival for some patients. Adolescent- and adult-onset neuroblastoma appeared to have specific characteristics associated with poorer outcomes compared to pediatric neuroblastoma. Nevertheless, complete disease control improved survival. The presence of a neuroblastic component in pheochromocytoma should be considered when making therapeutic management decisions. The development of specific tools/resources (Tumor Referral Board, Registry, biology, and trials with new agents or strategies) may help to improve outcomes for patients.
Sections du résumé
BACKGROUND
BACKGROUND
Adult- and adolescent-onset neuroblastomas are rare, with no established therapy. In addition, rare pheochromocytomas may harbor neuroblastic components. This study was designed to collect epidemiological, diagnostic and therapeutic data in order to better define the characteristics of malignant peripheral neuroblastic tumors (MPNT) and composite pheochromocytomas (CP) with MPNT.
PROCEDURE
METHODS
Fifty-nine adults and adolescents (aged over 15 years) diagnosed with a peripheral or composite neuroblastic tumor, who were treated in one of 17 institutions between 2000 and 2020, were retrospectively studied.
RESULTS
RESULTS
Eighteen patients with neuroblastoma (NB) or ganglioneuroblastoma (GNB) had locoregional disease, and 28 patients had metastatic stage 4 NB. Among the 13 patients with CP, 12 had locoregional disease. Fifty-eight percent of the population were adolescents and young adults under 24 years of age. The probability of 5-year event-free survival (EFS) was 40% (confidence interval: 27%-53%).
CONCLUSIONS
CONCLUSIONS
Outcomes were better for patients with localized tumor than for patients with metastases. For patients with localized tumor, in terms of survival, surgical treatment was the best therapeutic option. Multimodal treatment with chemotherapy, surgery, radiotherapy, and immunotherapy-based maintenance allowed long-term survival for some patients. Adolescent- and adult-onset neuroblastoma appeared to have specific characteristics associated with poorer outcomes compared to pediatric neuroblastoma. Nevertheless, complete disease control improved survival. The presence of a neuroblastic component in pheochromocytoma should be considered when making therapeutic management decisions. The development of specific tools/resources (Tumor Referral Board, Registry, biology, and trials with new agents or strategies) may help to improve outcomes for patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31074Subventions
Organisme : Association Grenobloise de Développement d'Etudes et Recherches en Médecine Infantile (AGDERMI)
Informations de copyright
© 2024 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Yan P, Qi F, Bian L, et al. Comparison of incidence and outcomes of neuroblastoma in children, adolescents, and adults in the United States: a Surveillance, Epidemiology, and End Results (SEER) program population study. Med Sci Monit. 2020;26:e927218.
Esiashvili N, Goodman M, Ward K, Marcus RB Jr, Johnstone PA. Neuroblastoma in adults: incidence and survival analysis based on SEER data. Pediatr Blood Cancer. 2007;49:41‐46.
Allan SG, Cornbleet MA, Carmichael J, Arnott SJ, Smyth JF. Adult neuroblastoma report of three cases and review of the literature. Cancer. 1986;57:2419‐2421.
Prestidge BR, Donaldson SS. Treatment results among adults with childhood tumors: a 20‐year experience. Int J Radiat Oncol Biol Phys. 1989;17:507‐514.
Raina V, Kumar R, Sharma SK, Sarkar C, Bal CS. Neuroblastoma in thoracic region in adults: a report of five cases. Ann Saudi Med. 1994;14:338‐341.
Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK. Neuroblastoma in adolescents and adults: the Memorial Sloan‐Kettering experience. Med Pediatr Oncol. 2003;41:508‐515.
Conter HJ, Gopalakrishnan V, Ravi V, Ater JL, Patel S, Araujo DM. Adult versus pediatric neuroblastoma: the M.D. Anderson Cancer Center experience. Sarcoma. 2014;2014:375151. doi:10.1155/2014/375151
Dosik GM, Rodriguez V, Benjamin RS, Bodey GP. Neuroblastoma in the adult: effective combination chemotherapy. Cancer. 1978;41:56‐63.
Polishchuk AL, Dubois SG, Haas‐Kogan D, Hawkins R, Matthay KK. Response, survival, and toxicity after iodine‐131‐metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer. 2011;117:4286‐4293.
Sorrentino S, Gigliotti AR, Sementa AR, et al. Neuroblastoma in the adult: the Italian experience with 21 patients. J Pediatr Hematol Oncol. 2014;36:e499‐e505.
Podda MG, Luksch R, Polastri D, et al. Neuroblastoma in patients over 12 years old: a 20‐year experience at the Istituto Nazionale Tumori of Milan. Tumori. 2010;96:684‐689.
Duan K, Dickson BC, Marrano P, Thorner PS, Chung CT. Adult‐onset neuroblastoma: report of seven cases with molecular genetic characterization. Genes Chromosomes Cancer. 2020;59:240‐248.
Suzuki M, Kushner BH, Kramer K, et al. Treatment and outcome of adult‐onset neuroblastoma. Int J Cancer. 2018;143:1249‐1258.
Rogowitz E, Babiker HM, Kanaan M, Millius RA, Ringenberg QS, Bishop M. Neuroblastoma of the elderly, an oncologist's nightmare: case presentation, literature review and SEER database analysis. Exp Hematol Oncol. 2020;3:20. doi:10.1186/2162‐3619‐3‐20
Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer. 1997;79:2028‐2035.
Lopez R, Karakousis C, Rao U. Treatment of adult neuroblastoma. Cancer. 1980;45:840‐844.
Rowe PH, Oram JJ, Scott GW. Neuroblastoma in adults. Postgrad Med J. 1979;55:579‐580.
Kushner BH, Kramer K, Modak S, Qin LX, Cheung NK. Differential impact of high‐dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemo‐resistant neuroblastoma. Cancer. 2010;116:3054‐3060.
Dhanasekar K, Visakan V, Tahir F, Balasubramanian SP. Composite phaeochromocytomas‐a systematic review of published literature. Langenbecks Arch Surg. 2022;407:517‐527.
Franquemont DW, Mills SE, Lack EE. Immunohistochemical detection of neuroblastomatous foci in composite adrenal pheochromocytoma‐neuroblastoma. Am J Clin Pathol. 1994;102:163‐170.
Mosse YP, Deyell RJ, Berthold F, et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61:627‐635.
Berbegall AP, Villamon E, Tadeo I, et al. Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration. Neoplasia. 2014;16:471‐480.
Campbell K, Gastier‐Foster JM, et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: a report from the Children's Oncology Group. Cancer. 2017;123:4224‐4235.
Cheung NK, Kushner BH, LaQuaglia M, et al. N7: a novel multi‐modality therapy of high‐risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001;36:227‐230.
Yu AL, Gilman AL, Ozkaynak F, et al. Long‐term follow‐up of a Phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high‐risk neuroblastoma: Children's Oncology Group study ANBL0032. Clin Cancer Res. 2021;27:2179‐2189.
Magnier O, Chabre O, Schiff I, et al. Management of a composite pheochromocytoma (pheochromocytoma/neuroblastoma) in adult patient recurring after several years: a complex case report. J Adolesc Young Adult Oncol. 2023;12:604‐610. doi:10.1089/jayao.2022.0059
Jin Q‐Y, Du S‐B, Yuan X‐J. Exploring the prognosis of neuroblastoma in adolescents and adults: a case series and literature review. Neoplasma. 2022;69:464‐473. doi:10.4149/neo_2021_210325N399
Dharmalingam P, Chenniappan AD, Alashetty S, Bidadi Lingappa K, Patil Okaly GV. Neuroblastoma in uncommon age group—a case series diagnosed on cytology. Diagn Cytopathol. 2023;51:629‐635. doi:10.1002/dc.25189
Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416:153‐159.
Bresler SC, Weiser DA, Huwe PJ, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014;26:682‐694. doi:10.1016/j.ccell.2014.09.019
Federico SM, Chen X, Easton J, et al. Association of age at diagnosis and stage of disease with ATRX mutations in neuroblastoma. J Clin Oncol. 2016;34:10525.
Mazzocco K, Defferrari R, Sementa AR, et al. Genetic abnormalities in adolescents and young adults with neuroblastoma: a report from the Italian Neuroblastoma Group. Pediatr Blood Cancer. 2015;62:1725‐1732. doi:10.1002/pbc.25552
Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012;307:1062‐1071.
De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008;99:1027‐1033.
Kohler JA, Rubie H, Castel V, et al. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study. Eur J Cancer. 2013;49:3671‐3679. doi:10.1016/j.ejca.2013.07.002
Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with non‐metastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol. 2011;29:449‐455. doi:10.1200/JCO.2010.29.5196
Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group project. Radiology. 2011;261:243‐257. doi:10.1148/radiol.11101352
Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86:364‐372.
Peuchmaur M, d'Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003;98:2274‐2281.
Ladenstein R, Pötschger U, Pearson ADJ, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high‐dose chemotherapy for high‐risk neuroblastoma (HR‐NBL1/SIOPEN): an international, randomised, multi‐arm, open‐label, phase 3 trial. Lancet Oncol. 2017;18:500‐514. doi:10.1016/S1470‐2045(17)30070‐0
Pasqualini C, Dufour C, Goma G, Raquin MA, Lapierre V, Valteau‐Couanet D. Tandem high‐dose chemotherapy with thiotepa and busulfan‐melphalan and autologous stem cell transplantation in very high‐risk neuroblastoma patients. Bone Marrow Transplant. 2016;51:227‐231. doi:10.1038/bmt.2015.264
Yu AL, Gilman AL, Ozkaynak MF, et al. Anti‐GD2 antibody with GM‐CSF, interleukin‐2, and isotretinoin for neuroblastoma. N Engl JMed. 2010;363:1324‐1334.
Ladenstein R, Pötschger U, Valteau‐Couanet D, et al. Interleukin 2 with anti‐GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high‐risk neuroblastoma (HR‐NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1617‐1629. doi:10.1016/S1470‐2045(18)30578‐3
Cheung NK, Cheung IY, Kramer K, et al. Key role for myeloid cells: phase II results of anti‐G(D2) antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer. 2014;135:2199‐2205. doi:10.1002/ijc.28851
Cheung NK, Kushner BH, Cheung IY, et al. Anti‐G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16:3053‐3060.
Lerman BJ, Li Y, Carlowicz C, et al. Progression‐free survival and patterns of response in patients with relapsed high‐risk neuroblastoma treated with irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony‐stimulating factor. J Clin Oncol. 2023;41:508‐516. doi:10.1200/JCO.22.01273
Mody R, Naranjo A, Van Ryn Collin MS, et al. Randomised phase II trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab (DIN) in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group (COG). Lancet Oncol. 2017;18:946‐957. doi:10.1016/S1470‐2045(17)30355‐8
Garrovillo K, Garrett J, Bollin K, Nasraty F, Sikand H. Dinutuximab in adult‐onset chemotherapy refractory high‐risk neuroblastoma. J Oncol Pharm Pract. 2020;26:2058‐2065. doi:10.1177/1078155220918920
Comstock JM, Willmore‐Payne C, Holden JA, Coffin CM. Composite pheochromocytoma: a clinicopathologic and molecular comparison with ordinary pheochromocytoma and neuroblastoma. Am J Clin Pathol. 2009;132:69‐73.
Bagatell R, London W, Wagner R, et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011;29:208‐213. doi:10.1200/JCO.2010.31.7107
Inserra A, Crocoli A. Palliative care. In: Sarnacki S, Pio L, eds. Neuroblastoma: Clinical and Surgical Management. Springer Nature; 2020:375‐383.
Illhardt T, Toporski J, Feuchtinger J, et al. Haploidentical stem cell transplantation for refractory/relapsed neuroblastoma. Biol Blood Marrow Transplant. 2018;24:1005‐1012. doi:10.1016/j.bbmt.2017.12.805
Del Bufalo F, De Angelis B, Caruana I, et al. GD2‐CART01 for relapsed or refractory high‐risk neuroblastoma. N Engl J Med. 2023;388:1284‐1295.
Gains JE, Moroz V, Aldridge MD, et al. A phase IIa trial of molecular radiotherapy with 177‐lutetium DOTATATE in children with primary refractory or relapsed high‐risk neuroblastoma. Eur J Nucl Med Mol Imaging. 2020;47:2348‐2357. doi:10.1007/s00259‐020‐04741‐x